| Title |
Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review
|
|---|---|
| Published in |
PharmacoEconomics, May 2014
|
| DOI | 10.1007/s40273-014-0160-z |
| Pubmed ID | |
| Authors |
Fabrice Smieliauskas, Chun-Ru Chien, Chan Shen, Daniel M. Geynisman, Ya-Chen Tina Shih |
| Abstract |
Over the last 15 years, a paradigm shift in oncology has led to the approval of dozens of targeted oral anti-cancer medications (OAMs), which have become the standard of care for certain cancers. While more convenient for patients than infused drugs, the possibility of non-adherence and the frequently high costs of targeted OAMs have proven controversial. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 3% |
| United Kingdom | 1 | 1% |
| Unknown | 77 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 15 | 19% |
| Researcher | 11 | 14% |
| Student > Postgraduate | 8 | 10% |
| Student > Ph. D. Student | 7 | 9% |
| Student > Bachelor | 6 | 8% |
| Other | 10 | 13% |
| Unknown | 23 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 36% |
| Nursing and Health Professions | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Economics, Econometrics and Finance | 4 | 5% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 10 | 13% |
| Unknown | 26 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 June 2016.
All research outputs
#6,134,638
of 22,755,127 outputs
Outputs from PharmacoEconomics
#671
of 1,816 outputs
Outputs of similar age
#58,370
of 226,936 outputs
Outputs of similar age from PharmacoEconomics
#9
of 29 outputs
Altmetric has tracked 22,755,127 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,816 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,936 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.